Human iPS Cell Line (Parkinson's Disease)
Human iPS Cell Line (Type 2 Diabetes)

Human iPS Cell Line (Amyotrophic Lateral Sclerosis)

产品代码: 30HU-004
Call for Price: 0592-7821662

产品规格

选择产品规格:
Cryopreserved, 0.5-1.0 million cells/vial

加入到愿望清单

发送产品给朋友

Product Description

Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells [1]. The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body.  iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells.

iXCells Biotechnologies is proud to offer human iPS cell lines derived from the human somatic cells (dermal fibroblasts, adipose-derived stem cells, peripheral blood mononuclear cells) from patients with Amyotrophic Lateral Sclerosis (ALS). The pertinent donor information is available upon request (This email address is being protected from spambots. You need JavaScript enabled to view it.).  These iPS cells are established from a single clone and expanded in feeder-free conditions.  The Certificate of Analysis is provided for each cell lot purchased. The cells have been fully characterized for their self-renewal and pluripotency (Figure 1). All the cells provided by iXCells are negative for mycoplasma, bacteria, yeast, and fungi. HIV-1, hepatitis B and hepatitis C.     

Normal human iPS cell lines are also available as separate products (Cat# 30HU-002). The currently available diseased specific iPS cell lines are derived from patients with Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), Alzheimers's Disease (AD), Parkinson's Disease (PD) (Cat# 30HU-003), Amyotrophic Lateral Sclerosis (ALS). More disease-specific iPS cell lines are under development.  We also provide custom iPSC generation and iPSC differentiation services to meet your needs.

iPSC Parkinson's Disease

Figure 1. iXCells human iPS cells are characterized by immunostaining with Oct4, Nanog, SSEA4, TRA-1-60-R, TRA-1-81.

 

Product Details

Tissue Origin Human iPS Cells derived from dermal fibroblasts, adipose-derived stem cells, or peripheral blood mononuclear cells
Package Size ~0.5-1.0x106 cells/vial
Shipped Cryopreserved
Storage Liquid nitrogen
Growth Properties Adherent
Media

Human iPSC Growth Medium (Cat # MD-0018)

MEF Conditioned Medium (Cat # MD-0015)

Human iPSC Feeder-Free Growth Medium (Cat # MD-0019)

Human iPSC Xeno-Free Growth Medium (Cat# MD-0074)

iMEF Feeder (CF1), irradiated (Cat # 10MU-001)

Matrigel Coated Plates (Cat # MD-0023)
 

 

References

[1] Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011 May; 8(5):409-12.

Manuals & Protocols

[1] Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011 May; 8(5):409-12.

Biological
Species Human (Diseased)